CNTX Stock Overview
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Context Therapeutics Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.38 |
52 Week High | US$1.69 |
52 Week Low | US$0.47 |
Beta | 2.13 |
1 Month Change | 22.29% |
3 Month Change | 20.17% |
1 Year Change | 128.39% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -72.90% |
Recent News & Updates
We're A Little Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate
Mar 27Here's Why Context Therapeutics (NASDAQ:CNTX) Must Use Its Cash Wisely
Sep 28Recent updates
We're A Little Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate
Mar 27Here's Why Context Therapeutics (NASDAQ:CNTX) Must Use Its Cash Wisely
Sep 28Will Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely?
Jun 05Context to focus on ELONA trial, CLDN6 program, extends cash runway into 1Q24
Sep 27We're Keeping An Eye On Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate
Sep 15Context Therapeutics GAAP EPS of -$0.25 in-line
Aug 11Context Therapeutics, Menarini to collaborate on breast cancer treatment combo trial
Aug 02Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth
May 28Context Therapeutics: A New Biotech Issue With A Low Valuation And Significant Potential
Nov 02Shareholder Returns
CNTX | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 20.2% | 1.2% | 0.4% |
1Y | 128.4% | 25.8% | 28.8% |
Return vs Industry: CNTX exceeded the US Pharmaceuticals industry which returned 23.9% over the past year.
Return vs Market: CNTX exceeded the US Market which returned 29.5% over the past year.
Price Volatility
CNTX volatility | |
---|---|
CNTX Average Weekly Movement | 10.7% |
Pharmaceuticals Industry Average Movement | 9.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CNTX's share price has been volatile over the past 3 months.
Volatility Over Time: CNTX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 5 | Martin Lehr | https://www.contexttherapeutics.com |
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy.
Context Therapeutics Inc. Fundamentals Summary
CNTX fundamental statistics | |
---|---|
Market cap | US$22.07m |
Earnings (TTM) | -US$23.96m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs CNTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CNTX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$23.96m |
Earnings | -US$23.96m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.50 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did CNTX perform over the long term?
See historical performance and comparison